Caladrius Biosciences Long-Term Debt 2011-2025 | CLBS

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Caladrius Biosciences

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
-	137 K	305 K	485 K	-	-	-	-	2.82 M	11.4 M	14.7 M	3.55 M	172 K	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
14.7 M	137 K	4.2 M

Quarterly Long-Term Debt Caladrius Biosciences

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
-	-	-	-	-	47 K	92 K	137 K	181 K	223 K	265 K	305 K	345 K	-	421 K	485 K	53 K	79 K	-	254 K	254 K	254 K	-	-	-	-	-	-	-	-	-	-	-	-	1.7 M	2.52 M	2.52 M	2.52 M	2.52 M	10.8 M	10.8 M	10.8 M	10.8 M	13.9 M	13.9 M	13.9 M	13.9 M	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
13.9 M	47 K	4.07 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
ARCA biopharma ABIO	755 K	-	1052.0 %	$ 415 M	USA
AbbVie ABBV	66.8 B	$ 223.01	-0.99 %	$ 395 B	USA
Alpine Immune Sciences ALPN	3.38 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	1.82 M	$ 4.68	1.85 %	$ 777 M	Canada
Aclaris Therapeutics ACRS	2.12 M	$ 3.38	3.21 %	$ 261 M	USA
AlloVir ALVR	16.6 M	-	4.14 %	$ 49.1 M	USA
Acasti Pharma ACST	410 K	-	4.01 %	$ 150 M	Canada
Adaptimmune Therapeutics plc ADAP	19.9 M	-	-15.15 %	$ 60.3 M	Britain
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
Aeglea BioTherapeutics AGLE	4 M	-	-	$ 1.01 B	USA
Alexion Pharmaceuticals, Inc. ALXN	2.42 B	-	-	$ 40.3 B	USA
Albireo Pharma ALBO	9.62 M	-	-0.23 %	$ 916 M	USA
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel
Aptorum Group Limited APM	130 K	$ 1.33	-1.48 %	$ 7.25 M	China
Alterity Therapeutics Limited ATHE	59.9 K	$ 3.4	1.49 %	$ 8.18 B	Australia
EyeGate Pharmaceuticals, Inc. EYEG	278 K	-	-1.52 %	$ 24.7 M	USA
AstraZeneca PLC AZN	17.5 B	$ 90.34	-1.28 %	$ 96.9 B	Britain
Amphastar Pharmaceuticals AMPH	614 M	$ 25.76	0.19 %	$ 1.25 B	USA
Anika Therapeutics ANIK	26.9 M	$ 9.53	-1.19 %	$ 140 M	USA
Brickell Biotech BBI	146 K	-	-5.38 %	$ 6.06 M	USA
BeiGene, Ltd. BGNE	166 M	-	0.49 %	$ 251 B	Cayman-islands
Biogen BIIB	6.3 B	$ 173.03	-2.55 %	$ 25.2 B	USA
BioVie BIVI	275 K	$ 1.54	-2.53 %	$ 2.28 M	USA
Bellicum Pharmaceuticals BLCM	25.7 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	22.7 M	-	-7.31 %	$ 87 M	USA
Aytu BioScience AYTU	10.9 M	$ 2.33	2.3 %	$ 14.6 M	USA
Arena Pharmaceuticals ARNA	14.7 M	-	-6.81 %	$ 3.04 B	USA
Baudax Bio BXRX	1.52 M	-	0.59 %	$ 63 K	USA
Avenue Therapeutics ATXI	2.03 M	-	-52.27 %	$ 4.45 M	USA
Catalyst Biosciences CBIO	199 K	$ 15.32	5.73 %	$ 1.01 B	USA
Институт стволовых клеток человека ISKJ	175 M	-	-	-	Russia
ChromaDex Corporation CDXC	12 K	-	-0.88 %	$ 598 M	USA
Axon Enterprise AXON	41.4 M	$ 586.28	3.15 %	$ 44.4 B	USA
Cerus Corporation CERS	11.7 M	$ 2.14	13.23 %	$ 395 M	USA
Checkpoint Therapeutics CKPT	2.47 M	-	-	$ 169 M	USA
Celldex Therapeutics CLDX	2.36 M	$ 28.33	0.5 %	$ 1.82 M	USA
Cellectar Biosciences CLRB	494 K	$ 3.81	-5.35 %	$ 46.6 M	USA
Clovis Oncology CLVS	437 M	-	-7.23 %	$ 13 M	USA
Cortexyme CRTX	13.4 M	-	-1.05 %	$ 67.1 M	USA
Benitec Biopharma BNTC	495 K	$ 12.91	0.78 %	$ 531 M	USA
Cytokinetics, Incorporated CYTK	93.2 M	$ 60.38	0.11 %	$ 6.76 M	USA
BioNTech SE BNTX	231 M	$ 95.9	0.17 %	$ 27.2 B	Germany
Deciphera Pharmaceuticals DCPH	22.4 M	-	-	$ 2.18 B	USA
Biohaven Pharmaceutical Holding Company Ltd. BHVN	627 M	$ 11.55	8.86 %	$ 747 M	USA
Dynavax Technologies Corporation DVAX	26.4 M	$ 10.89	-0.09 %	$ 1.42 B	USA
Eloxx Pharmaceuticals ELOX	8.56 M	-	-5.68 %	$ 8.28 M	USA
Acer Therapeutics ACER	146 K	-	2.71 %	$ 14 M	USA